1. Report of the quality standards subcommittee of the American Academy of Neurology;Practice Advisory: Thrombolytic therapy for acute ischemic stroke—Summary Statement;Neurology,1996
2. On behalf of the American Heart Association Stroke Council. Expansion of the Time Window for Treatment of Acute Ischemic Stroke with Intravenous Tissue Plasminogen Activator;del Zoppo;A Science Advisory From the American Heart Association/American Stroke Association Stroke,2009
3. ATLANTIS Trials Investigators; ECASS Trials Investigators; NINDS rt-PA Study Group Investigators. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials;Hacke;Lancet,2004
4. Treatment time-specific number needed to treat estimates for tissue plasminogen activator therapy in acute stroke based on shifts over the entire range of the modified Rankin Scale;Lansberg;Stroke,2009
5. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials;Lees;Lancet,2010